Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable

Executive Summary

FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act

You may also be interested in...



Drug Proprietary Name Selection: Draft Guidance Calls For Simulation Studies

FDA draft guidance on developing proprietary drug names recommends series of steps for sponsors to evaluate a proposed name; safety review includes testing name with healthcare professionals.

PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown

The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.

PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown

The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.

Related Content

UsernamePublicRestriction

Register

PS047944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel